We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stellar Biotechnologies Announces Investor Relations Agreement
News

Stellar Biotechnologies Announces Investor Relations Agreement

Stellar Biotechnologies Announces Investor Relations Agreement
News

Stellar Biotechnologies Announces Investor Relations Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stellar Biotechnologies Announces Investor Relations Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TheBiotechPanel is a full and comprehensive provider of investor relations services, and will assist the Company in fostering productive, continuing dialogues with analysts, brokers, investors and other financial professionals.

TheBiotechPanel will receive a monthly retainer of US $8,000 during the term of the IR Agreement ($48,000 for first six months). The IR Agreement is subject to review and approval by the TSX Venture Exchange.

Darrell Brookstein, Stellar's Executive VP, Corporate Development & Finance, said, "We are very pleased to have Frank Rothmaier, the founder and editor of TheBiotechPanel.com and his experienced partner, Ray Campos, on board to help Stellar reach out to European investors as we move forward with our U.S. registration which will enable a new group of professional investors and analysts to review the merits of our securities. TheBiotechPanel will bring 'biopharma fluency' in German and Spanish, and enable us to reach tens of thousands of European retail investors with demonstrated interest in U.S. small-cap biotech companies."

Frank Rothmaier, founder and Managing Director of TheBiotechPanel, said, "I have been enthusiastically following the dynamic Stellar growth story for almost two years now, and have been identifying investors for their KLH, therapeutic vaccine and potential active immune platform story during that time. I'm excited to bring the Stellar team to present before our European investors. I believe institutional as well as retail investors will become quite interested in Stellar Biotechnologies as it develops to the next stage in 2012."

Advertisement